Table 3.

Hypertension risk with angiogenesis inhibitors.

	Molecular target	Incidence of hypertension	Relative risk of hypertension	Reference
Bevacizumab	Anti-VEGF-A antibody	25.4% (21.3–30.1)	7.5 (4.2-13.4)	(36)
Sorafenib	B-Raf, FLT-1, FLT-3, FLT-4, KDR, KIT, PDGFR-A, PDGFR-B, FGFR, c-fms	22.5% (19.5–25.9)	3.9 (2.6-5.9)	(37)
Sunitinib	ABL-1, c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-3, FLT-4, FGFR, SRC, c-smc	29%	–	(38)
Ramucirumab	Anti-KDR antibody	21.3%	2.7 (2.3-3.2)	(39)

VEGF, anti-vascular endothelial growth factor; -, not available; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor.